Xeris Pharmaceuticals Inc XERS

$9.08 -0.17 (-1.84%)

Valuation

Market cap
1,686,460,000
Revenue TTM
$291,850,000
Net income TTM
$550,000
PE ratio
136.57
Forward PE
136.57
Profit margin
0.19%
Debt to equity
-25.96

Trading

Volume
1,803,500
Avg volume
2,231,156
Day's range
$9.03 – $9.34
Shares out
182,320,000
Stochastic %K
22%
Beta
0.53
Analysts
Strong Sell
Price target
$12.29

Price

Company profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary p...

Show more

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
844 445 5704
Website
https://www.xerispharma.com
Address
1375 West Fulton Street, Suite 1300, Chicago, United States

Latest news

Stocktwits

PJACOB01 Oct 3, 2:58 PM
$XERS There is no reason for increase in share count as they have internal funding for furhter trials. THey should also stop with this nonsense of inducement grants. That is pure pickpocketing of shareholders.
0 replies
BuyThisOne Oct 3, 11:57 AM
$XERS On thing to keep in mind here. Even if the market cap gets to something like $10 billion in 2030 that might only be a share price of about $40 as there may be upwards of 250 million shares at that point. Very difficult to say where this will be but if they can achieve say $1.40 EPS on $750 million revenue with a levo approval maybe we could see $50 a share. Of course we have to factor in excitement levels and that could push the stock to be overvalued at points in time just like when it hit $10 last year. With the steady 200%+ runs and 50% drawdowns this has been a great place to make money as a trade or buy and hold and I believe that will continue for at least the next decade unless a buyout/merger of course. $40 in 2030 from here is 45% annual returns. If you bought at $1 in 2023 that will be about 70% CAGR. If you bought $1000 in Home depot in 1981 you would have about $16 mil or about 24% CAGR to put that in perspective. $1000 at 70% for 26 years is a billion. Good luck
0 replies
tommyb1234 Oct 3, 10:49 AM
$XERS The current price does not even value potential XP 8121 revenues .. And still undervalues the stock, I feel good about Orincess. If you google "problems with taking levothyroxine orally"... It is too hard to get the right dose, and both having a low dose or too high, a dose is bad... too high a dose, and you end up with hyperthyroidism. You have to space your dosage. Apart from meals like at least thirty minutes, you have to adjust your day. Most will go the option to het the once weekly injection. I guess just the people who are really scared of needles won't do it. But they'll come around. 72% Strongly prefer the once weekly injection per phase 2. I could see the beginning of phase 3 announcement before year end.. as catalyst I hope
0 replies
BiochemKev Oct 3, 12:31 AM
Maybe $XERS had to get their inducement grants out before they can sell 😅
0 replies
E_Ross Oct 2, 8:15 PM 0 replies
meistermell Oct 2, 7:31 PM
$XERS New base forming, every dip gets bought, still undervalued despite the recent run. Fair value after takeover interest $11-$12 before premium, will keep rising with every quarter.
0 replies
Universaal Oct 2, 5:53 PM
$VSTM $XERS $PSNL extremely overpriced and overbought biotech needs a correction big time
2 replies
SparkyReturns Oct 2, 5:48 PM
$XERS Curling up....
0 replies